Spondyloarthritis & psoriatic arthritis
Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis
Authors' conclusion
Higher 3-month SDL were detected in responders.
Study context
- Population
- Psoriatic arthritis (PsA) patients commencing adalimumab (ADL) or etanercept (ETN), UK observational study OUTPASS
- Participants
- 97 vs 104
- Exposure
- Responders vs non-responders: 3-month serum drug levels of adalimumab and etanercept
- ETNn = 97
- ADLn = 104
- Outcome
- Relationship between ADL and ETN SDL and response (PsARC or EULAR criteria); optimal non-trough SDL thresholds
- Follow-up
- 3 months
Methodological detailsnon-trough serum samples, ROC analysis
- Non-trough serum samples
- ROC analysis
Main finding
As reported in the abstract
| Group | AUC (PsARC responders vs non-responders) | Threshold (PsARC) | Specificity (PsARC) | Sensitivity (PsARC) | AUC (EULAR good vs non-/moderate) | Threshold (EULAR) | Specificity (EULAR) | Sensitivity (EULAR) |
|---|---|---|---|---|---|---|---|---|
| ETN | 0.70 | 1.8 µg/ml | 63% | 69% | 0.65 | 2.0 µg/ml | 57% | 69% |
| ADL | 0.63 | 3.6 µg/ml | 48% | 81% |
AUC (PsARC responders vs non-responders)
ETN0.70
ADL— not stated in the abstract
Threshold (PsARC)
ETN1.8 µg/ml
ADL— not stated in the abstract
Specificity (PsARC)
ETN63%
ADL— not stated in the abstract
Sensitivity (PsARC)
ETN69%
ADL— not stated in the abstract
AUC (EULAR good vs non-/moderate)
ETN0.65
ADL0.63
Threshold (EULAR)
ETN2.0 µg/ml
ADL3.6 µg/ml
Specificity (EULAR)
ETN57%
ADL48%
Sensitivity (EULAR)
ETN69%
ADL81%
- ETN: PsARC good responders had significantly higher 3-month serum drug levels (SDL) vs non-responders
- P = 0.006
- ETN: EULAR good responders had significantly higher 3-month SDL vs non-responders
- P = 0.020
- ADL: EULAR good responders had significantly higher 3-month SDL
- P = 0.049
Observational data: associations, not effects.
Original publication
Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis. Rheumatology (Oxford). Published 9 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →